home > epc > autumn 2008 > market epowers
European Pharmaceutical Contractor

Market ePowers

The biopharmaceutical industry is ideally situated to take advantage of the power of electronic marketing. Pharma companies will reap the rewards of developing highly effective, robust and scaleable electronic marketing programmes designed to meet today’s challenges.

These hurdles include:

  • Escalating competition for innovation
  • Promotion of new drugs or other products as soon as they are out of R&D
  • The rapid spread of globalisation requiring immediate international marketing efforts
  • Continually changing regulatory mandates that necessitate nimble response
  • Growing pressure to demonstrate financial performance despite finite or shrinking budgets

Whether a biotech or pharma business is in start-up mode, building demand or working toward an exit strategy, electronic marketing can play a central role in educating the worldwide market about pharmaceutical breakthroughs, establishing brand awareness, driving qualified leads, creating customer loyalty and increasing company valuation.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
With more than 17 years of communications experience, Margaret Osborn brings clients a wealth of brand development, strategic planning, and traditional and electronic marketing expertise. As Vice President of Synergy Marketing Group Inc, based in Indianapolis, Indiana, she specialises in marketing for high-tech, scientific and industrial B2B firms, including global companies in the life sciences, healthcare, biotechnology and pharmaceutical sectors.
Margaret Osborn
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences


Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >>

Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement